Non-HDL cholesterol and LDL cholesterol in the dyslipidemic classification in patients with nonalcoholic fatty liver disease

Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors

(2017) T. Du et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk

(2015) Tingting Du et al.   Cardiovascular Diabetology

Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population

(2014) Takashi Hisamatsu et al.   ATHEROSCLEROSIS

Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

(2014) George Thanassoulis et al.   Journal of the American Heart Association

Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis

(2013) Andrew Paul DeFilippis et al.   ATHEROSCLEROSIS

Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease

(2013) Shira Zelber-Sagi et al.   LIVER INTERNATIONAL

Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease

(2013) Edward Fisher et al.   SEMINARS IN LIVER DISEASE

Non–High-Density Lipoprotein Cholesterol as a Biomarker for Nonalcoholic Steatohepatitis

(2012) Kathleen E. Corey et al.   Clinical Gastroenterology and Hepatology

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

(2012) S. Matthijs Boekholdt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance

(2011) Sung Hee Choi et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: The Framingham heart study

(2010) Elizabeth K. Speliotes et al.   HEPATOLOGY

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

(2010) Yuki Kimura et al.   JOURNAL OF GASTROENTEROLOGY

Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity

(2010) Piia Simonen et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis

(2009) Koji Fujita et al.   HEPATOLOGY

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

(2008) J. D. Brunzell et al.   DIABETES CARE